FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

|   | OMB Number:              | 3235-0287 |
|---|--------------------------|-----------|
|   | Estimated average burden |           |
| ı | hours per response:      | 0.5       |

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person*  Ingargiola Luisa  (Last) (First) (Middle) |         |       | 2. Issuer Name and Ticker or Trading Symbol BioCorRx Inc. [ BICX ]  |  | tionship of Reporting Person(s)<br>all applicable)<br>Director | (s) to Issuer         |  |  |
|---|---------|-------|---|--|--|-----------------------|--|--|
|   |         |       | 3. Date of Earliest Transaction (Month/Day/Year) 06/30/2023   | A  | Officer (give title below)                                     | Other (specify below) |  |  |
| 2390 EAST ORANGEWOOD AVENUE SUITE 500 (Street)                                      |         |       | 4. If Amendment, Date of Original Filed (Month/Day/Year)  | 6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person |  |                       |  |  |
| ANAHEIM   | CA      | 92806 | Rule 10b5-1(e) Transaction Indication   |  |  |                       |  |  |
| (City)  | (State) | (Zip) | Check this box to indicate that a transaction was made pursuant to a contra affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | struction or written plan that is intended to satisfy the  |  |                       |  |  |

# Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | on Date, Transaction Code (Instr. |   | 4. Securities Ad<br>Disposed Of (D |               |       | Securities<br>Beneficially Owned<br>Following Reported | Form: Direct (D)<br>or Indirect (I)<br>(Instr. 4) | Beneficial<br>Ownership |  |
|---------------------------------|--|---|-----------------------------------|---|------------------------------------|---------------|-------|--|---|-------------------------|--|
|                                 |  |   | Code                              | v | Amount                             | (A) or<br>(D) | Price | Transaction(s)<br>(Instr. 3 and 4)                     |   | (Instr. 4)              |  |
| Common Stock, par value \$0.001 | 06/30/2023                                 |   | A <sup>(1)</sup>                  |   | 2,891                              | A             | \$0   | 39,390   | D   |                         |  |

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

|  | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | Transaction<br>Code (Instr.<br>8) |     | Derivative |                     | Expiration Date<br>(Month/Day/Year) |       | 7. Title and Amount of<br>Securities Underlying<br>Derivative Security<br>(Instr. 3 and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |
|--|--|--|---|-----------------------------------|-----|------------|---------------------|-------------------------------------|-------|--|--|---|--|--|--|--|
|  |  |  |   | Code V                            | (A) | (D)        | Date<br>Exercisable | Expiration<br>Date                  | Title | Amount<br>or<br>Number<br>of Shares  |  | Transaction(s)<br>(Instr. 4)                        |  |  |  |  |

## **Explanation of Responses:**

#### Remarks:

/s/ Luisa Ingargiola 07/05/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>1.</sup> These shares were issued to Ms. Ingargiola pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Ingargiola. As compensation for her services, Ms. Ingargiola shall be issued, upon the last day of each fiscal quarter, provided Ms. Ingargiola is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to \$5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was \$1.73.